ARM
26.9.2022 22:41:37 CEST | Business Wire | Press release
Arm today announced the appointment of new Board members Karen Dykstra, former Chief Financial and Administrative Officer of AOL and Jeff Sine, Co-Founder and Partner of Raine Group, effective immediately. These highly qualified leaders bring a diverse range of expertise to Arm as the company prepares for a potential public listing.
Arm Chief Executive Officer (CEO) Rene Haas said: “I extend a warm welcome to Karen and Jeff, both exceptional business leaders who will bring a depth and breadth of experience to the Arm Board.”
Arm also today announced the appointment of Jason Child as Chief Financial Officer (CFO). Child has more than 30 years of experience in leadership at high growth companies and scaling global finance functions. Child will join Arm on November 2, 2022 and lead the company’s global finance and IT organizations, reporting to Haas.
Haas added, “Jason is an experienced leader in global finance and technology. His extensive experience in financial management at public companies and IPO execution will be invaluable in preparation for a potential public listing. I look forward to working with him as part of the Arm leadership team as we continue to define the future of computing, built on Arm.”
Child will replace current CFO Inder Singh who will remain at Arm in an advisory role and assist in the transition through November before moving to a new opportunity.
Haas said, “I’d like to thank Inder for his contributions and leadership over these past few years. He has helped the company navigate many changes since joining in 2019, including building a strong organization with upgraded systems and processes in the finance, IT and cybersecurity teams. We wish him all the best moving forward.”
Child most recently served as senior vice president and CFO at Splunk from 2019. Prior to Splunk, Child held multiple CFO positions including at Groupon, which he helped to take public in 2011 and as CFO at Amazon International.
“Since its founding, Arm has had an incredible history of innovation and leadership in the semi-conductor industry,” said Child. “Arm is a world-class, category leader and I am thrilled to join as CFO during this exciting time for the company.”
About Karen Dykstra
Ms. Dykstra previously served as Chief Financial and Administrative Officer of AOL, a web portal and online service provider. Prior to AOL, she was a Partner at Plainfield Asset Management, and served as Chief Operating Officer and Chief Financial Officer of Plainfield Direct, Plainfield’s business development company. She previously spent over 25 years with Automatic Data Processing (ADP), a provider of human capital management solutions to employers, serving most recently as Chief Financial Officer. Ms. Dykstra is currently a director on the boards of VMware and Gartner, and has also served on the boards of Boston Properties, Crane and AOL.
About Jeff Sine
Mr. Sine is the Co-Founder and Partner of The Raine Group, a global merchant bank focused on technology, media and communications. Prior to founding Raine, he served as Vice Chairman and Global Head of Technology, Media & Telecom Investment Banking at UBS Investment Bank, was a Managing Director at Morgan Stanley and was an attorney at Sullivan & Cromwell in New York and London. Mr. Sine currently serves on the boards of many Raine portfolio companies and subsidiaries. He also serves on the boards of National Public Radio (NPR) (Vice-Chair), ITHAKA, Educational Testing Service (ETS) (Chair), American University and The Manhattan Theatre Club.
About Jason Child
Jason Child’s career spans 30 years across all aspects of global finance and strategy, accounting, capital markets/treasury, IPO execution and investor relations. He has extensive experience in scaling disruptive technologies within enterprise software/SaaS, e-commerce, local commerce, consumer hardware/IOT, and online residential real estate. He most recently served as senior vice-president and CFO at Splunk, a technology company specializing in application management, security and compliance, as well as business and web analytics. Before his executive leadership roles, Jason spent more than 11 years leading various global finance teams at Amazon, and served as CFO of Amazon International. Jason has served as a member of the board of directors of Coupang, Inc., an e-commerce company, since April 2022. He holds B.A. from the Foster School of Business at the University of Washington, where he currently serves on the Global Advisory Board.
About Arm
Arm technology is defining the future of computing. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 230 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners, we are enabling artificial intelligence to work everywhere, and in cybersecurity, we are delivering the foundation for trust in the digital world – from chip to cloud. The future is being built on Arm.
All information is provided "as is" and without warranty or representation. This document may be shared freely, attributed and unmodified. Arm is a registered trademark of Arm Limited (or its subsidiaries). All brands or product names are the property of their respective holders. © 1995-2022 Arm Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005775/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
